Unlimited Bio News

Unlimited Bio placed in the top 100 XPRIZE Healthspan teams

Unlimited Bio is thrilled to be among the Top 100 teams in the XPRIZE Healthspan contest, standing shoulder-to-shoulder with leading universities and public biotech companies.

Elite Academic Partners. Finalists include Brigham and Women’s Hospital (Harvard Medical School affiliate, $876 M NIH funding), University of Tokyo, Osaka University and Salk Institute, underscoring the world-class research in this cohort.

Publicly Traded Longevity Innovators. We join the ranks of GI Innovation (>$300 M raised), Longevity Innovator (LogIN) on the Tokyo Stock Exchange, Longeveron on U.S. markets, and now BioAge Labs, a California-based clinical-stage biotech pioneering therapies from human longevity datasets.

Unlimited Bio’s Edge: Launched in 2024 on a lean seed budget, we’ve already produced four gene-therapy constructs (VEGF, Follistatin, Klotho, BDNF) for an unprecedented multi-gene mouse trial kicking off in two weeks, demonstrating that speed and cost-efficiency can rival even the deepest-pocketed labs.

As we gear up for in vivo testing, this achievement spotlights Unlimited Bio’s ability to compete with billion-dollar institutions and public companies, proving that nimble innovation can lead the longevity revolution!